Last reviewed · How we verify

BNT162b2 Pfizer-BioNTech/Comirnaty

KK Women's and Children's Hospital · FDA-approved active Biologic Under review Quality 0/100

BNT162b2 Pfizer-BioNTech/Comirnaty is a mRNA vaccine Biologic drug developed by KK Women's and Children's Hospital. It is currently FDA-approved for Prevention of COVID-19 in individuals 6 months of age and older, Booster vaccination for COVID-19 in previously vaccinated individuals.

BNT162b2 is an mRNA vaccine that instructs cells to produce the SARS-CoV-2 spike protein, triggering an immune response to prevent COVID-19 infection.

BNT162b2, also known as Comirnaty, is a vaccine antigen that targets the spike glycoprotein of the SARS-CoV-2 virus. It is used to prevent COVID-19, a condition studied in various clinical trials, including the COVID-19 Vaccines Safety Tracking (CoVaST) study.

At a glance

Generic nameBNT162b2 Pfizer-BioNTech/Comirnaty
SponsorKK Women's and Children's Hospital
Drug classmRNA vaccine
TargetSARS-CoV-2 spike protein (S protein)
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhaseFDA-approved

Mechanism of action

The vaccine delivers lipid nanoparticle-encapsulated messenger RNA encoding the full-length spike protein of SARS-CoV-2. Upon intramuscular injection, the mRNA is translated by host cells to produce spike protein antigen, which activates both CD8+ T-cell and B-cell mediated immunity. This generates neutralizing antibodies and cellular immunity against the virus, reducing risk of infection and severe disease.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about BNT162b2 Pfizer-BioNTech/Comirnaty

What is BNT162b2 Pfizer-BioNTech/Comirnaty?

BNT162b2 Pfizer-BioNTech/Comirnaty is a mRNA vaccine drug developed by KK Women's and Children's Hospital, indicated for Prevention of COVID-19 in individuals 6 months of age and older, Booster vaccination for COVID-19 in previously vaccinated individuals.

How does BNT162b2 Pfizer-BioNTech/Comirnaty work?

BNT162b2 is an mRNA vaccine that instructs cells to produce the SARS-CoV-2 spike protein, triggering an immune response to prevent COVID-19 infection.

What is BNT162b2 Pfizer-BioNTech/Comirnaty used for?

BNT162b2 Pfizer-BioNTech/Comirnaty is indicated for Prevention of COVID-19 in individuals 6 months of age and older, Booster vaccination for COVID-19 in previously vaccinated individuals.

Who makes BNT162b2 Pfizer-BioNTech/Comirnaty?

BNT162b2 Pfizer-BioNTech/Comirnaty is developed and marketed by KK Women's and Children's Hospital (see full KK Women's and Children's Hospital pipeline at /company/kk-women-s-and-children-s-hospital).

What drug class is BNT162b2 Pfizer-BioNTech/Comirnaty in?

BNT162b2 Pfizer-BioNTech/Comirnaty belongs to the mRNA vaccine class. See all mRNA vaccine drugs at /class/mrna-vaccine.

What development phase is BNT162b2 Pfizer-BioNTech/Comirnaty in?

BNT162b2 Pfizer-BioNTech/Comirnaty is FDA-approved (marketed).

What are the side effects of BNT162b2 Pfizer-BioNTech/Comirnaty?

Common side effects of BNT162b2 Pfizer-BioNTech/Comirnaty include Injection site pain, Fatigue, Headache, Myalgia, Chills, Fever.

What does BNT162b2 Pfizer-BioNTech/Comirnaty target?

BNT162b2 Pfizer-BioNTech/Comirnaty targets SARS-CoV-2 spike protein (S protein) and is a mRNA vaccine.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing